Related Experiment Video
Updated: May 13, 2026

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
MYO5B is epigenetically silenced and associated with MET signaling in human gastric cancer
Wenjie Dong1, Liping Wang, Ruizhe Shen
1Department of Internal Medicine-Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Background:
Our previous study has shown that MYO5B is downregulated in gastric cancer. However, the mechanism by which the expression of MYO5B was inhibited remains unknown.
Methods:
Inspection of the human MYO5B locus uncovered a large and dense CpG island within the 5' region of this gene. Methylation-specific PCR (MSP) and bisulfite sequencing (BSP) were used for determination of MYO5B promoter methylation in gastric cancer cell lines and gastric cancer samples. Involvement of histone H3 methylation in those cell lines were examined by ChIP assay.
Results:
The densely methylated MYO5B promoter region was confirmed by MSP and BSP. Enhanced gene expression was detected when the cells were treated with the DNA-demethylating agent 5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA), a histone deacetylase inhibitor. Knockdown of MYO5B expression in gastric cancer cells expressing endogenous MYO5B inhibits HGF-stimulated MET degradation, concomitant with sustained c-MET levels and signaling.
Conclusion:
The results of our study showed for the first time that MYO5B is epigenetically silenced in gastric cancer cells by aberrant DNA methylation and histone modification. Inactivation of MYO5B expression in gastric cancer cells expressing endogenous MYO5B inhibits HGF-stimulated MET degradation, concomitant with sustained c-MET levels and signaling.
Insights
Gastric cancer cells epigenetically silence MYO5B via DNA methylation and histone modification. This silencing impacts MET degradation and signaling pathways, revealing a novel mechanism in cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Previous research indicated MYO5B downregulation in gastric cancer.
- The precise mechanism of MYO5B expression inhibition was previously unknown.
Purpose of the Study:
- To investigate the epigenetic mechanisms silencing MYO5B in gastric cancer.
- To elucidate the functional consequences of MYO5B inactivation on MET signaling.
Main Methods:
- Analysis of the MYO5B promoter CpG island.
- Methylation-specific PCR (MSP) and bisulfite sequencing (BSP) to assess promoter methylation.
- ChIP assay to examine histone modifications.
- Treatment with DNA-demethylating agent (5-aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A).
Main Results:
- Aberrant DNA methylation of the MYO5B promoter was confirmed in gastric cancer.
- Demethylation agents and histone deacetylase inhibitors restored MYO5B expression.
- MYO5B knockdown in gastric cancer cells led to sustained c-MET levels by inhibiting HGF-stimulated MET degradation.
Conclusions:
- MYO5B is epigenetically silenced in gastric cancer through DNA methylation and histone modifications.
- Inactivation of MYO5B affects MET degradation and signaling pathways.
- This epigenetic silencing represents a novel mechanism in gastric cancer pathogenesis.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Epigenetic Regulation
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic cells are...
MicroRNAs